Phosphodiesterase 5 inhibitors in vascular systemic disorders

被引：4
|
作者：
Allanore, Yannick [1 ]
机构：
[1] Univ Paris 05, INSERM U1016, Serv Rhumatol, Hop Cochin, F-75014 Paris, France
来源：
JOINT BONE SPINE | 2012年 / 79卷 / 04期
关键词：
Phosphodiesterase; Nitric oxide; Pulmonary hypertension; Raynaud's phenomenon; Sildenafil; Tadalafil; PULMONARY ARTERIAL-HYPERTENSION; RAYNAUDS-PHENOMENON RESISTANT; DOUBLE-BLIND; SILDENAFIL; THERAPY; TADALAFIL; SCLEROSIS; EFFICACY;
D O I：
10.1016/j.jbspin.2011.12.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 340
页数：3
相关论文
共 50 条
  • [41] Editorial: Tachyphylaxis and phosphodiesterase type 5 inhibitors
    Steers, WD
    JOURNAL OF UROLOGY, 2002, 168 (01): : 207 - 207
  • [42] Optimizing response to phosphodiesterase type 5 inhibitors
    Sadovsky R.
    Current Sexual Health Reports, 2007, 4 (1) : 1 - 6
  • [43] The use of phosphodiesterase 5 inhibitors with concomitant medications
    Corona, G.
    Razzoli, E.
    Forti, G.
    Maggi, M.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (09) : 799 - 808
  • [44] Phosphodiesterase-5 Inhibitors: Future Perspectives
    Konstantinos, Giannitsas
    Petros, Perimenis
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (30) : 3540 - 3551
  • [45] Phosphodiesterase type 5 inhibitors and kidney disease
    Afsar, Baris
    Ortiz, Alberto
    Covic, Adrian
    Gaipov, Abduzhappar
    Esen, Tarik
    Goldsmith, David
    Kanbay, Mehmet
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2015, 47 (09) : 1521 - 1528
  • [46] Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors
    Jackson, G
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (12B): : 32M - 36M
  • [47] ADMET considerations for phosphodiesterase-5 inhibitors
    Rezvanfar, Mohammad Amin
    Rahimi, Hamid Reza
    Abdollahi, Mohammad
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (10) : 1231 - 1245
  • [48] Cardiac Uses of Phosphodiesterase-5 Inhibitors
    Schwartz, Bryan G.
    Levine, Laurence A.
    Comstock, Gary
    Stecher, Vera J.
    Kloner, Robert A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (01) : 9 - 15
  • [49] Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction
    Aversa, Antonio
    Bruzziches, Roberto
    Pili, Marcello
    Spera, Giovanni
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (27) : 3467 - 3484
  • [50] Chronic dosing of phosphodiesterase type 5 inhibitors
    Donatucci C.F.
    Current Sexual Health Reports, 2008, 5 (2) : 65 - 69
12345